Trial · NCT07569536
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 30-day mortality | Day 30 after randomization | Vital status at day 30 after randomization. |
| Secondary | 72-hour mortality | 72 hours after randomization | Vital status at 72 hours after randomization |
| Secondary | Vasopressor exposure | 6, 12 and 24 hours after randomization | Cumulative vasopressor dose and peak vasopressor dose expressed as norepinephrine-equivalent dose (NEE score) |
| Secondary | Use of vasopressin or recue therapies | From randomization to day 30 | Proportion of patients requiring vasopressin or any therapy for refractory shock during follow-up |
| Secondary | Mean arterial pressure (MAP) | Baseline, 6 hours, 12 hours and 24 hours after randomization | Evolution of mean arterial pressure (MAP) and MAP to norepinephrine-equivalent (Neq) dose ration (MAP/Neq) to assess vasopressor responsiveness |
| Secondary | Vasopressor-free days | Day 0 to day 30 | Number of days without vasopressor therapy during the first 30 days following randomization |
| Secondary | Mechanical ventilation-free days | Day 0 to day 30 | Number of days without mechanical ventilation during the first 30 days following randomization |
| Secondary | Blood lactate concentration | 6 hours, 12 hours and 24 hours after randomization | Arterial blood lactate levels |
| Secondary | SOFA score | Baseline and day 3 after randomization | Evolution of organ failure assessed using the Sequential Organ Failure Assessment (SOFA) score (minimum 0, maximum 24). |
| Secondary | Cumulative fluid balance | Day 0 to day 5 | Difference between total fluid intake and total fluid output |
| Secondary | New-onset or persistent atrial fibrillation | Within 14 days after randomization | Occurrence of new-onset atrial fibrillation or persistence of atrial fibrillation requiring clinical management. |
| Secondary | ICU and 90-day mortality | At day 3 and day 90 after randomization | Vital status at Intensive Care Unit (ICU) discharge and at 90 days following randomization. |
| Secondary | Clinically significant bradycardia | During the treatment period (until day 30) | Occurrence of bradycardia defined as heart rate \< 50 bpm requiring therapeutic intervention |
| Secondary | Coma-free days | Day 0 to day 30 or ICU discharge | Number of days without coma up to day 30 |
| Secondary | ICU delirium | Daily until day 30 or ICU discharge | Occurrence of delirium during ICU stay assessed daily using the CAP-ICU in patients with RASS≥ -3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07569536/registered